ClinicalTrials.gg
RecruitingNCT06996236Updated Nov 9, 2026

Brimonidine Eye Drops in the Prevention of Myopia Progression

A Phase 2 interventional study of Treatment with brimonidine eye drops 0.025% in Myopia, sponsored by Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal. Recruiting at 1 site in Spain. Open to participants aged 6 Years to 14 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal · Phase 2, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Nov 9, 2026Now RecruitingStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
6 Years to 14 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 26 studies in Myopia with a site in Spain — 4 open to participants now, 9 under way, 1 of them phase 3. Myopia · Spain.

Planned enrollment
17th of 23
40 · median 60
Started
2025
with 3 others
Phase 2
Only one
of the 26
Registered
23rd of 26
by date
Lead sponsor
1 of 26
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

Among the 26 studies in Myopia with a site in Spain, this one is the 17th largest by planned enrollment of the 23 interventional ones that give a count, is one of 4 that started in 2025, is the only one in phase 2, and was the 23rd registered.

Myopia

1,166 studies on the registry are indexed under Myopia; 228 are open to participants now.

Browse Myopia studies →

Open to participants now

4 of the 26 studies in Myopia with a site in Spain are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 124 Myopia studies recruiting now, 20 (16%) set no upper age limit and 103 (83%) stop at 75 or younger; 85 take children under 18; 53 take healthy volunteers.

This study: 6 Years to 14 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Myopia with a site in Spain, or all of them as a file.
02

Study summary

Study to determine the efficacy of alpha-2 adrenergic drugs (brimonidine) in the prevention of myopia progression. Given that the drugs used so far have limited efficacy and side effects (loss of near vision, photophobia), it may be an interesting contribution to such treatment at low cost, and to avoid the expense of managing the complications of myopia that develop throughout life.

Read the detailed description

For the prevention of myopia progression it is reasonable to use a local topical route in eye drops, since it avoids the occurrence of systemic side effects and the drug reaches the corresponding receptors at a higher concentration via the topical route. This route of administration has been previously used in animal models and in humans, with atropine, pirenzepine and brimonidine.

The concentration proposed (0.025%) in this study is the one used with relative success without side effects for atropine in humans, and has also been used in animal models for brimonidine itself. As this is a first study, the investigators do not propose the use of higher concentrations at this time. The proposed regimen (once a day) is the one commonly used in the treatment of myopia. Although at the concentration used it is used 3-4 times a day in other indications of brimonidine eye drops, given the longer duration of this treatment and the fact that it is a first study, the investigators opted for the once-daily regimen.

Since eye growth is relatively slow, a treatment duration of 1 to 2 years is necessary to assess the effect of the drug on myopia progression and eye axial length variation. In addition, in case of therapeutic use of brimonidine eye drops, it would be necessary to use it for long periods of time, not less than 2 years, so it is convenient to evaluate its behavior when used in long term regimens.

03

Conditions studied

  • Myopia

Browse trials for

04

Who can participate

Ages eligible
6 Years to 14 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 6 to ≤ 14 years
  • Patients who, after having received information about the design, the purposes of the study, the possible risks that may arise from it and that at any time they may refuse to cooperate, give written consent to participate in the study (the patient older than 12 years and the legal representative)
  • Myopia ≥ -1. 50 Diopters of spherical equivalent, ranging from -1.50 to -5.50 D
  • Astigmatism with a cylinder power ≤ -1.50 Diopters
  • Anisometropia (refractive difference between both eyes) in spherical equivalent ≤ 1.25 Diopters
  • Visual acuity (CVA) > 0.3 logMAR (0.5 on Snellen scale).
  • Intraocular pressure \< 20 mm Hg
  • In women of childbearing age negative urine pregnancy test performed within 7 days prior to the start of treatment
  • Women and men with partners of childbearing age must agree to use a highly effective method of (such as surgical sterilization, double barrier method, oral contraceptives or hormonal contraceptive implants) and to continue using them until 6 months after the last dose of treatment.

Exclusion criteria

Exclusion Criteria:

  • Presence of any other ocular pathology (other than myopia)
  • History of allergy to the medications and used in the study
  • History of previous therapy for myopia using eye drops, contact lenses or multifocal or bifocal glasses
  • Amblyopia (2 or more lines of difference in visual acuity between both eyes, on logMAR scale, with optical correction)
  • Any of the following situations present at the time: prolonged ocular hyperemia, prolonged ocular irritation, ocular infections - mucopurulent discharge in ocular tissues, ocular pain, vision changes/alterations other than myopia
  • Any clinical situation that at the investigator's discretion advises against participation.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    Lumobry 0.25 mg/ml eye drops solution

    Lumobry 0.25 mg/ml eye drops solution

    Drug: Treatment with brimonidine eye drops 0.025%

Interventions

  • DrugTreatment with brimonidine eye drops 0.025%

    Drug page: BrimonidineStudies of BrimonidineBrimonidine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Treatment with brimonidine eye drops 0.025%, instilled once a day at night, with simultaneous occlusion of the lower lacrimal punctum to avoid its systemic absorption, for 2 years.

06

What researchers measure

Primary outcomes

  1. Effect of brimonidine eye drops 0.025% on myopia progression in children aged 6 to 14 years

    Progression of myopia (change in spherical equivalent of refractive error) measured every 6 months (Auto-refractometry and Subjective refraction)

    Time frame: 24 months

Secondary outcomes

  1. Progression of various ocular biometric variables in the children of the treated and control groups,

    Myopia progression by measuring every 6 months: change in axial eye length

    Time frame: 24 months

  2. Progression of various ocular biometric variables in the children of the treated and control groups

    Description: Myopia progression by measuring every 6 months: visual acuity

    Time frame: 24 months

  3. Progression of various ocular biometric variables in the children of the treated and control groups

    Description: Myopia progression by measuring every 6 months: pupillometry/accommodation

    Time frame: 24 Months

  4. Progression of various ocular biometric variables in the children of the treated and control groups

    Description: Myopia progression by measuring every 6 months: corneal topography

    Time frame: 24 Months

  5. Progression of various ocular biometric variables in the children of the treated and control groups

    Description: Myopia progression by measuring every 6 months: intraocular pressure

    Time frame: 24 Months

  6. Progression of various ocular biometric variables in the children of the treated and control groups

    Collecting adverse events

    Time frame: 24 Months

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Dec 2025 (actual). Primary completion is estimated for Jul 2027, 19 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: start Jul 2025 → Dec 2025 and primary completion Jul 2026 → Jul 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2025
First posted
May 30, 2025
StartActual
Dec 17, 2025was Jul 2025
Primary completionEst.
Jul 2027was Jul 2026
CompletionEst.
Jul 2027
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 9, 2026
Sites
1 site added, 1 site removed
Show site
  • Hospital Universitario Ramón y Cajal · Madrid, Spain
Show 1 removed
  • Hospital Universitario Ramón y Cajal · Madrid, Spain
Nov 9, 2026
Start date
Jul 2025→Dec 17, 2025 (actual)
Nov 9, 2026
Primary completion
Jul 2026→Jul 2027
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Not yet recruiting→Recruiting
    1 site added, 1 site removed
    Show site
    • Hospital Universitario Ramón y Cajal · Madrid, Spain
    Show 1 removed
    • Hospital Universitario Ramón y Cajal · Madrid, Spain
    Start date Jul 2025→Dec 17, 2025 (now actual)
    Primary completion Jul 2026→Jul 2027
    + 3 other changes: verification date, registry dates and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06996236
Lead sponsor
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Responsible party
Sponsor
First posted
May 30, 2025
Start date
Dec 17, 2025
Primary completion
Jul 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Nov 9, 2026

Study contacts

Jaime Tejedor Fraile, Md
Contact
tejedor.jaime@gmail.com
913368679 / 913369023
Jaime Tejedor Fraile, MD
principal investigator · Hospital Universitario Ramon y Cajal

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brimonidine

Start the discussion